Related Experiment Video
Updated: Jun 8, 2025

08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.3K
Proton Radiation Therapy for Head and Neck Cancers
Muhammad Sami1, Muhammad Yousuf2, Qasim Hashmi3
1Medicine, Kingston Hospital, London, GBR.
Cureus
|November 4, 2024
Summary
Proton therapy (PT) offers a more accurate and less toxic radiotherapy option for head and neck (HnN) cancers compared to intensity-modulated radiation therapy (IMRT). This review compiles evidence on PT
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Head and neck (HnN) cancers represent a significant global health burden.
- Proton therapy (PT) is an advanced radiation modality with potential benefits for HnN cancer treatment.
- Existing literature on PT for HnN cancers necessitates a consolidated comparison with intensity-modulated radiation therapy (IMRT) regarding clinical outcomes and toxicities.
Purpose of the Study:
- To compile and summarize existing literature comparing proton therapy (PT) and intensity-modulated radiation therapy (IMRT) for head and neck (HnN) cancers.
- To evaluate toxicities, overall survival (OS), local control (LC), and quality of life (QoL) in HnN cancer patients treated with PT.
Main Methods:
- Literature search conducted using the keyword 'proton therapy for head and neck cancers'.
- Compilation and summarization of studies focusing on toxicities, OS, LC, and QoL.
- Comparative analysis of PT versus IMRT based on gathered evidence.
Main Results:
- Proton therapy (PT) allows for precise tumor targeting in HnN cancers, minimizing radiation exposure to surrounding healthy tissues.
- The pencil beam scanning technique in PT enables accurate tumor localization.
- PT demonstrates potential for reduced acute and late toxicities compared to IMRT.
Conclusions:
- Proton therapy (PT) is a preferable radiotherapy modality for HnN cancer patients due to its precision and reduced toxicity profile.
- Further comparative studies are needed to fully elucidate the long-term benefits of PT in terms of overall survival and quality of life.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
149
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
149
Positron Emission Tomography
4.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.0K

